merck - Search News

Merck, Keytruda and WSJ

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Reuters on MSN · 1d

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Business Insider · 1d

Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in

Wall Street Journal · 1d

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its drug Keytruda.

Seeking Alpha on MSN · 1d

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,

Merck KGaA Forecasts Earnings, Sales Growth

The Wall Street Journal on MSN · 14h

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and strict cost discipline.

Reuters on MSN · 14h

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production. The German group said in a statement that 2025 earnings before interest,

Seeking Alpha · 4h

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor

Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Fierce Biotech9h

Merck KGaA fails midphase lupus trial, says totality of data support further development

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

The Reporter2h

Merck seeks to trade wetlands for potential to add parking or building

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...

12h

Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

12d

Is Merck Stock a Buy?

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck expects cancer therapy Keytruda to be part of government price setting in 2026

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Merck Manuals: What Patients Need to Know About Sinusitis and Sinus Infections

A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Merck, Keytruda and WSJ

Merck KGaA Forecasts Earnings, Sales Growth

Related topics